OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I dont think 6p will be available much longer?

Make that 7p.the recent buying suggests good news on the way?

Does someone know the patient reaction to first 5x dosing....or is the reported Sanofi-Aventis $1.35 Billion set aside for Eye-Care Acquisitions...ringing bells?

Anyone keeping an eye on this constant buying?.. Expect news.this is not the OXB that I know7p gone...

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2010
Share this article

TIDMOXB

RNS Number : 1393C

Oxford Biomedica PLC

02 March 2011


2011/OB/04
EMBARGOED UNTIL 7.00AM 2 MARCH 2011 2 MARCH 2011


OXFORD BIOMEDICA PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2010

Oxford, UK - 2 March 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces its preliminary results for the year ended 31 December 2010.

Operational highlights:

ProSavin(R) : Parkinson's disease

-- Safety and tolerability endpoints sustained for >2 years, now extended to nine patients

-- Two-year Phase I/II data indicate long-term efficacy at lowest (1x) dose level

-- Improvements in "ON" time and quality of life, with stable or reduced L-DOPA, in all cohorts to date

-- Enhanced administration procedure is safe and reduced surgery delivery time at the 2x dose

-- Data Monitoring Committee supports progression to higher (5x) dose level cohort with initial data expected mid-2011

Ocular gene therapies: partnered with sanofi-aventis

-- RetinoStat(R) IND approval received from the FDA

-- StarGen(TM) CTA and IND dossiers submitted to AFSSAPS and FDA

-- First data from RetinoStat(R) Phase I study expected H1 2012

TroVax(R) : cancer

-- Phase II study in hormone refractory prostate cancer initiated with initial data expected from mid-2012

-- Positive TRIST analyses published in Clinical Cancer Research

-- Multiple collaborative studies expected to start in 2011

Financial highlights(1) :

-- Revenue of GBP11.2 million (2009: GBP19.1 million including exceptional revenue GBP10.1 million)

-- Research & development costs incl. exceptional items of GBP19.9 million (2009: GBP18.3 million)

-- Exceptional loss (impairment) of GBP3.9 million (2009: exceptional profit of GBP6.0 million)

-- Net loss before exceptional items of GBP6.3 million (2009: GBP9.5 million)

-- Net loss after exceptional items of GBP10.3 million (2009: GBP3.5 million)

-- Net cash burn(2) of GBP13.0 million (2009: net cash generated(2) GBP3.0 million)

-- Net cash(3) of GBP12.3 million (2009: GBP25.3 million)

1. Audited financial results

2. Net cash used in /generated from operating activities plus sales and purchases of non-current assets and interest received

3. Cash, cash equivalents and available for sale investments

Post-period end highlights:

-- Fundraising of GBP20 million before expenses, completed on 10 January 2011

-- Acquisition of manufacturing facility for GBP1.9 million, completed in February 2011

John Dawson, Chief Executive Officer at Oxford BioMedica, said: "2010 has been a successful year for Oxford BioMedica and our progress to date underlines the Company's strong fundamentals. We continue to build the value of our lead programmes and expect key data and milestones over the next 12-18 months for ProSavin(R) , TroVax(R) and the ocular products partnered with sanofi-aventis. Thanks to existing and new shareholders we were also able to secure GBP20 million of funding which will enable us to maximise the opportunities ahead, including the enhancement of our specialist manufacturing processes. With exciting future prospects, we remain committed to driving momentum and delivering value for shareholders."

-Ends

All looks very good, except they haven't got a regular product to sell, so all of the above is window-dressing before the shop opens, (as it were). I hold this and recent placing, but the sp is refusing to leap into double figures despite what looks like a "good deal" =looking to the future, with that manufacturing plant.
Having their stuff made in-house should provide them with a strong hand in negotiations.....initially they can sell direct can't they?
But still the sp is not really responding well. Maybe a case of soon taking some nasty medicine - Oh No!
EDIT(5May2011)-AGM today and SP is barely 5p despite all that Cash and Potential. Recent ann. Director Options look like they've caught the same bug affecting most of the AIM market Co's. - that of fine words and no Deeds. We need a return to shareholder power - by which I mean those that pay their own money for shares....which is Thee and Me...not Institutions or Freebe handouts.
EDIT(19Jy2011)- 6.6p Yikes! up 10% on Buy, but probably not after Dealer charges, etc... However, general markets are jumpy, yet again.
EDIT (18Nov2011):- Oh deary, 5p for quite some while - no news, little excitement.

With 60mil shares traded over the last five days inclusive of today there is news on the waythat is a done deal!OXB have always had news leaks and this appears to be something substantial

Slight SP movement but hunch says a big day round the cornerrememberI will never use all my luck up!! Dyor.

Oh ffs tabby another wing and a prayer job you got in at a much higher price.

Stick to mks.

Dil what are you like on logarithms or compound multiplication?not too good I would presumemy combined accounts are showing a double digit profit at this moment in time on OXBare you forgetting I am invincible!with you posting on the MDX thread along with the nobssuggest you are trying to provoke a situation

Im too happy mate!!! Family retired on BLNX alonethen SER came along.whoooooooshplus another on the wayIll tell you about it later. But I am still capable of telling a few to fcuk off!! So dont get cheeky..

Dilwhat are you one day on three months off?listenafter speaking with my usual crew I have a hunch that there is significant interest in this stock No ramp intended

Keep an eye on the trading patternsOXB are not very good at keeping secretsdont say I havent pointed you in the right directionJKDI am also telling you now OK?no silly post after the event please

Watch this space

Continued one-sided trading.what gives?

Same again today!

Same again today!

Very interesting on the ITV websiteTrovax is back in voguegood story for OXB...

http://www.itv.com/meridian-west/new-lung-cancer-medicine79290/

It's true there was a decent rise mid-2011 (July Sun?) but it's been falling ever since.

OXB just never seems to keep hold of its rises, so I guess it mainly MM's having a laugh.
At these prices you'd expect folk to be falling over themselves, but I made a nice turn recently and sold half - should have sold them all.
+ Still have large holding from earlier and higher, say average 20p but reported deals will transform this foal into a thoroughbred winner (er, I hope!).

However, there is not much evidence others think the same...

The MMs are certainly at it to-day - 4 mil buys 1 mil sells and down 25%.

I don't understand why there's been a great fall, I thought the clinical update was very positive - to the extent if they'd risen to 6p I might be a Buyer - but clearly the Market as a whole thinks this (result?) is Negative - were they expecting a OTC pill?
- oh no, I get it -Happy Pills, that's what they should have been making - and we've yet to hear if their "new facility" has be finished.

My comment yesterday, was premature, eh? "..However, there is not much evidence others think the same..."

So, who were part of tabasco's 'crew?'

Did try and tell him that drug comps were a waste of time but of course he knew better, hey ho.

Anyone understand why the recent News has been treated as "bad"?
EDIT(10Feb2012)- A.Wood steps aside as FD; pity. +I bought some more last month as near cash-value approaches.
EDIT(15Feb2012)-Oh deary, Dir add a few to his 300,000shares (£9K)DYOR. Not exactly a big invt?
EDIT(17April2012) - Big rise on PhI/II PD results, but these were expected, weren't they? Back soon to 3p I guess.
EDIT,(6Jn2012)- 3p04 now just, below latest buys, to be expected with the Greeks rioting again, soon. I'm hopeful it will rise=double figures like 60p before we're Out.